Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease

Todd E. Meyerrose, Marie Roberts, Kevin K. Ohlemiller, Carole A. Vogler, Louisa Wirthlin, Jan Nolta, Mark S. Sands

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Bone marrow-derived mesenchymal stem cells (MSCs) are a promising platform for cell- and gene-based treatment of inherited and acquired disorders. We recently showed that human MSCs distribute widely in a murine xenotransplantation model. In the current study, we have determined the distribution, persistence, and ability of lentivirally transduced human MSCs to express therapeutic levels of enzyme in a xenotransplantation model of human disease (nonobese diabetic severe combined immunodeficient mucopolysaccharidosis type VII [NOD-SCID MPSVII]). Primary human bone marrow-derived MSCs were transduced ex vivo with a lentiviral vector expressing either enhanced green fluorescent protein or the lysosomal enzyme β-glucuronidase (MSCs-GUSB). Lentiviral transduction did not affect any in vitro parameters of MSC function or potency. One million cells from each population were transplanted intraperitoneally into separate groups of neonatal NODSCID MPSVII mice. Transduced MSCs persisted in the animals that underwent transplantation, and comparable numbers of donor MSCs were detected at 2 and 4 months after transplantation in multiple organs. MSCs-GUSB expressed therapeutic levels of protein in the recipients, raising circulating serum levels of GUSB to nearly 40% of normal. This level of circulating enzyme was sufficient to normalize the secondary elevation of other lysosomal enzymes and reduce lysosomal distention in several tissues. In addition, at least one physiologic marker of disease, retinal function, was normalized following transplantation of MSCs-GUSB. These data provide evidence that transduced human MSCs retain their normal trafficking ability in vivo and persist for at least 4 months, delivering therapeutic levels of protein in an authentic xenotransplantation model of human disease.

Original languageEnglish (US)
Pages (from-to)1713-1722
Number of pages10
JournalStem Cells
Volume26
Issue number7
DOIs
StatePublished - Jul 2008

Fingerprint

Heterologous Transplantation
Mesenchymal Stromal Cells
Enzymes
Therapeutics
Mucopolysaccharidosis VII
Transplantation
Bone Marrow
Mesenchymal Stem Cell Transplantation
Retinal Diseases
Glucuronidase
Proteins

Keywords

  • Adult stem cells
  • Ex vivo gene therapy
  • Lentiviral vector
  • Lysosomal storage disease
  • Mesenchymal stem cells
  • Xenotransplantation

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Molecular Medicine

Cite this

Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. / Meyerrose, Todd E.; Roberts, Marie; Ohlemiller, Kevin K.; Vogler, Carole A.; Wirthlin, Louisa; Nolta, Jan; Sands, Mark S.

In: Stem Cells, Vol. 26, No. 7, 07.2008, p. 1713-1722.

Research output: Contribution to journalArticle

Meyerrose, Todd E. ; Roberts, Marie ; Ohlemiller, Kevin K. ; Vogler, Carole A. ; Wirthlin, Louisa ; Nolta, Jan ; Sands, Mark S. / Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. In: Stem Cells. 2008 ; Vol. 26, No. 7. pp. 1713-1722.
@article{a12555b4941348a1ba8c856cd4f6c848,
title = "Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease",
abstract = "Bone marrow-derived mesenchymal stem cells (MSCs) are a promising platform for cell- and gene-based treatment of inherited and acquired disorders. We recently showed that human MSCs distribute widely in a murine xenotransplantation model. In the current study, we have determined the distribution, persistence, and ability of lentivirally transduced human MSCs to express therapeutic levels of enzyme in a xenotransplantation model of human disease (nonobese diabetic severe combined immunodeficient mucopolysaccharidosis type VII [NOD-SCID MPSVII]). Primary human bone marrow-derived MSCs were transduced ex vivo with a lentiviral vector expressing either enhanced green fluorescent protein or the lysosomal enzyme β-glucuronidase (MSCs-GUSB). Lentiviral transduction did not affect any in vitro parameters of MSC function or potency. One million cells from each population were transplanted intraperitoneally into separate groups of neonatal NODSCID MPSVII mice. Transduced MSCs persisted in the animals that underwent transplantation, and comparable numbers of donor MSCs were detected at 2 and 4 months after transplantation in multiple organs. MSCs-GUSB expressed therapeutic levels of protein in the recipients, raising circulating serum levels of GUSB to nearly 40{\%} of normal. This level of circulating enzyme was sufficient to normalize the secondary elevation of other lysosomal enzymes and reduce lysosomal distention in several tissues. In addition, at least one physiologic marker of disease, retinal function, was normalized following transplantation of MSCs-GUSB. These data provide evidence that transduced human MSCs retain their normal trafficking ability in vivo and persist for at least 4 months, delivering therapeutic levels of protein in an authentic xenotransplantation model of human disease.",
keywords = "Adult stem cells, Ex vivo gene therapy, Lentiviral vector, Lysosomal storage disease, Mesenchymal stem cells, Xenotransplantation",
author = "Meyerrose, {Todd E.} and Marie Roberts and Ohlemiller, {Kevin K.} and Vogler, {Carole A.} and Louisa Wirthlin and Jan Nolta and Sands, {Mark S.}",
year = "2008",
month = "7",
doi = "10.1634/stemcells.2008-0008",
language = "English (US)",
volume = "26",
pages = "1713--1722",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "7",

}

TY - JOUR

T1 - Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease

AU - Meyerrose, Todd E.

AU - Roberts, Marie

AU - Ohlemiller, Kevin K.

AU - Vogler, Carole A.

AU - Wirthlin, Louisa

AU - Nolta, Jan

AU - Sands, Mark S.

PY - 2008/7

Y1 - 2008/7

N2 - Bone marrow-derived mesenchymal stem cells (MSCs) are a promising platform for cell- and gene-based treatment of inherited and acquired disorders. We recently showed that human MSCs distribute widely in a murine xenotransplantation model. In the current study, we have determined the distribution, persistence, and ability of lentivirally transduced human MSCs to express therapeutic levels of enzyme in a xenotransplantation model of human disease (nonobese diabetic severe combined immunodeficient mucopolysaccharidosis type VII [NOD-SCID MPSVII]). Primary human bone marrow-derived MSCs were transduced ex vivo with a lentiviral vector expressing either enhanced green fluorescent protein or the lysosomal enzyme β-glucuronidase (MSCs-GUSB). Lentiviral transduction did not affect any in vitro parameters of MSC function or potency. One million cells from each population were transplanted intraperitoneally into separate groups of neonatal NODSCID MPSVII mice. Transduced MSCs persisted in the animals that underwent transplantation, and comparable numbers of donor MSCs were detected at 2 and 4 months after transplantation in multiple organs. MSCs-GUSB expressed therapeutic levels of protein in the recipients, raising circulating serum levels of GUSB to nearly 40% of normal. This level of circulating enzyme was sufficient to normalize the secondary elevation of other lysosomal enzymes and reduce lysosomal distention in several tissues. In addition, at least one physiologic marker of disease, retinal function, was normalized following transplantation of MSCs-GUSB. These data provide evidence that transduced human MSCs retain their normal trafficking ability in vivo and persist for at least 4 months, delivering therapeutic levels of protein in an authentic xenotransplantation model of human disease.

AB - Bone marrow-derived mesenchymal stem cells (MSCs) are a promising platform for cell- and gene-based treatment of inherited and acquired disorders. We recently showed that human MSCs distribute widely in a murine xenotransplantation model. In the current study, we have determined the distribution, persistence, and ability of lentivirally transduced human MSCs to express therapeutic levels of enzyme in a xenotransplantation model of human disease (nonobese diabetic severe combined immunodeficient mucopolysaccharidosis type VII [NOD-SCID MPSVII]). Primary human bone marrow-derived MSCs were transduced ex vivo with a lentiviral vector expressing either enhanced green fluorescent protein or the lysosomal enzyme β-glucuronidase (MSCs-GUSB). Lentiviral transduction did not affect any in vitro parameters of MSC function or potency. One million cells from each population were transplanted intraperitoneally into separate groups of neonatal NODSCID MPSVII mice. Transduced MSCs persisted in the animals that underwent transplantation, and comparable numbers of donor MSCs were detected at 2 and 4 months after transplantation in multiple organs. MSCs-GUSB expressed therapeutic levels of protein in the recipients, raising circulating serum levels of GUSB to nearly 40% of normal. This level of circulating enzyme was sufficient to normalize the secondary elevation of other lysosomal enzymes and reduce lysosomal distention in several tissues. In addition, at least one physiologic marker of disease, retinal function, was normalized following transplantation of MSCs-GUSB. These data provide evidence that transduced human MSCs retain their normal trafficking ability in vivo and persist for at least 4 months, delivering therapeutic levels of protein in an authentic xenotransplantation model of human disease.

KW - Adult stem cells

KW - Ex vivo gene therapy

KW - Lentiviral vector

KW - Lysosomal storage disease

KW - Mesenchymal stem cells

KW - Xenotransplantation

UR - http://www.scopus.com/inward/record.url?scp=55049118090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55049118090&partnerID=8YFLogxK

U2 - 10.1634/stemcells.2008-0008

DO - 10.1634/stemcells.2008-0008

M3 - Article

C2 - 18436861

AN - SCOPUS:55049118090

VL - 26

SP - 1713

EP - 1722

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 7

ER -